Table 2.
Effects of chromium, magnesium and their combination on anthropometric measurements and hsCRP,8-iso-PGF2a in impaired glucose tolerance people after 3 months of intervention.
| n | BMI (kg/m2) | Fasting glucose (mmol/L) | Fasting Insulin (uU/ml) | 2 h Glucose (mmol/L) | HOMA-IR | Waist hip ratio | |
|---|---|---|---|---|---|---|---|
| Placebo | 29 | 24.29 ± 3.43 | 6.38 ± 1.32 | 12.29 ± 6.48 | 9.00 ± 1.83 | 3.17 ± 2.24 | 0.90 ± 0.07 |
| Chromium | 29 | 23.37 ± 2.27 | 5.66 ± 2.30 | 10.95 ± 4.90 | 8.88 ± 2.91 | 3.25 ± 2.56 | 0.88 ± 0.05 |
| Magnesium | 28 | 23.50 ± 2.45 | 5.33 ± 0.63 | 9.63 ± 5.51* | 8.52 ± 2.51 | 2.91 ± 1.34 | 0.88 ± 0.05 |
| Chromium + Magnesium | 29 | 23.40 ± 2.66 | 5.02 ± 1.40* | 8.99 ± 5.36* | 7.00 ± 2.60* | 1.48 ± 0.86* | 0.84 ± 0.06* |
| p | 0.52 | 0.024 | 0.156 | 0.027 | 0.043 | 0.017 | |
| n | Triglyceride (mmol/L) | Total cholesterol (mmol/L) | LDL-cholesterol (mmol/L) | HDL-cholesterol (mmol/L) | hsCRP (mg/L) | 8-iso-PGF2a (pg/ml) | |
| Placebo | 29 | 1.98 ± 1.13 | 4.90 ± 0.98 | 3.13 ± 0.90 | 1.38 ± 0.34 | 2.59 ± 1.21 | 61.71 ± 7.96 |
| Chromium | 29 | 1.55 ± 0.78 | 5.27 ± 1.23 | 3.51 ± 1.24 | 1.46 ± 0.30 | 2.50 ± 1.34 | 52.83 ± 5.72* |
| Magnesium | 28 | 1.53 ± 1.21 | 5.59 ± 1.28 | 3.80 ± 1.17 | 1.49 ± 0.35 | 1.74 ± 0.88* | 56.33 ± 6.46* |
| Chromium + Magnesium | 29 | 1.57 ± 0.48 | 4.81 ± 0.75 | 3.23 ± 0.61 | 1.67 ± 0.51* | 1.47 ± 0.65* | 40.37 ± 6.12* |
| p | 0.215 | 0.059 | 0.105 | 0.048 | 0.000 | 0.000 |
Data as mean ± SEM and as median and interquartile range.
HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein; OGTT, oral glucose tolerance test;HOMA-IR = fasting plasma insulin (µIU/mL) × fasting plasma glucose(mmol/L) × 22.5.
*p < .05 was considered to be statistically significant.